Company / Capital Expenditures
Protalix BioTherapeutics, Inc. Capital Expenditures History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$1.1M
FY2025
5-year range
$627.0K / $1.5M
FY2021-FY2025
Trend
+83.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has fluctuated over the past 10 years, ranging from $464,000 in FY2017 to $2M in FY2015.
Based on SEC 10-K filings.
$1M in FY2025 with a 10-year CAGR of -4.9%.
Declined from $1M to $1M over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +20.6%
- 5-Year CAGR
- +10.9%
- 10-Year CAGR
- -4.9%
Key checks
Key Insights
- 5-year CAGR of +10.9%, indicating consistent growth.
- In FY2025, capital expenditures increased 83.0% year-over-year.
- Peak capital expenditures was recorded in FY2015.
- Lowest capital expenditures in the period was in FY2017.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.1M | +83.0% |
| FY2024 | $628.0K | -57.0% |
| FY2023 | $1.5M | +122.7% |
| FY2022 | $655.0K | +4.5% |
| FY2021 | $627.0K | -8.6% |
| FY2020 | $686.0K | -29.4% |
| FY2019 | $971.0K | +109.3% |
| FY2017 | $464.0K | -40.9% |
| FY2016 | $785.0K | -58.5% |
| FY2015 | $1.9M | -8.6% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026